Palbociclib 75mg, 100mg, 125mg Capsules — First-in-Class CDK4/6 Inhibitor for HR-Positive HER2-Negative Advanced and Metastatic Breast Cancer in Combination With Endocrine Therapy
Alpelisib 150mg, 200mg, 250mg+50mg Film-Coated Tablets — PI3Kα-Selective Inhibitor for HR-Positive HER2-Negative PIK3CA-Mutated Advanced or Metastatic Breast Cancer in Combination With Fulvestrant
Dabrafenib 50mg, 75mg Capsules — BRAF V600 Kinase Inhibitor for BRAF V600-Mutated Metastatic Melanoma, NSCLC, Anaplastic Thyroid Cancer and Other BRAF V600E-Mutated Solid Tumours — Used in Combination With Meqsel (Trametinib)
Abemaciclib 50mg, 100mg, 150mg Film Coated Tablets — CDK4/6 Inhibitor for HR-Positive HER2-Negative Breast Cancer in Combination With Endocrine Therapy and as Monotherapy